Columvi Market Report 2026

Columvi Market Overview

• The Columvi market growth in the historic period has been driven by limitations of conventional lymphoma therapies, advancement in monoclonal antibody engineering • Market expansion is supported by growth in relapsed lymphoma cases, expansion of bispecific platforms • Growth Driver: Rising Incidence Of Hematologic Malignancies Driving Growth Of The Columvi Market • Market Trend: Innovative Advancements In The Columvi Market  • North America was the largest region in 2025 and Europe is the fastest growing region.

What Is Covered Under Columvi Market?

Columvi (glofitamab-gxbm) is a prescription medication used for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults who have received at least two prior treatments. It is a bispecific monoclonal antibody that targets CD20 on B-cells and CD3 on T-cells, facilitating an immune response against cancer cells. Administered via intravenous infusion, it offers a novel option in immunotherapy for hard-to-treat B-cell lymphomas. The main indications for columvi include non-hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Non-Hodgkin lymphoma (NHL) is a type of cancer that originates in the lymphatic system, which includes the lymph nodes, spleen, and bone marrow. It can be used both as bispecific antibody therapeutics and targeted cd20-cd3 therapies and is distributed through various channels such as hospital pharmacies, retail pharmacies, and specialty pharmacies.

What Is The Columvi Market Growth Forecast?

The growth in the forecast period can be attributed to growth in relapsed lymphoma cases, expansion of bispecific platforms, combination immunotherapy research, specialty oncology center growth, precision oncology investments. Major trends in the forecast period include rising adoption of bispecific antibody therapies, expansion of immunotherapy in relapsed lymphoma, focus on t cell redirecting treatments, hospital based advanced oncology care, growing use of targeted cd20 therapies.

What Are The Drivers Of The Columvi Market?

The increasing incidence of hematologic malignancies is expected to boost the growth of the columvi market going forward. Hematologic malignancies refer to cancers originating from blood-forming cells, primarily affecting the bone marrow and lymphatic system. The rising cases of hematologic malignancies are due to factors such as an aging population, increased exposure to carcinogens, lifestyle changes such as obesity, improved detection methods, and geographic variations in incidence rates. Columvi is used in hematologic malignancies to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and large B-cell lymphoma (LBCL) after two or more systemic therapies. For instance, in March 2024, according to the Leukaemia & Lymphoma Society, a US-based professional organization, an estimated 187,740 people in the US are projected to be diagnosed with leukemia, lymphoma, or myeloma in 2024. These cases will comprise 9.4% of the 2,001,140 total new cancer diagnoses expected in the country. Therefore, the increasing incidence of hematologic malignancies will drive the growth of the columvi industry. The rising aging population is expected to propel the growth of the columvi market going forward. The aging population refers to a demographic group characterized by a higher proportion of individuals aged 65 and older, often due to increased life expectancy and declining birth rates. The aging population is increasing due to advancements in healthcare and living standards that extend life expectancy, combined with declining birth rates in many regions. Columvi benefits the aging population by providing an effective treatment option for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), a condition more common in older adults, through targeted and durable therapeutic strategies. For instance, in October 2024, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, one in six people worldwide will be aged 60 years or older by 2030, with the global population in this age group rising from 1 billion in 2020 to 1.4 billion. By 2050, the number of people aged 60 and above is projected to double, reaching 2.1 billion. Additionally, the population of individuals aged 80 years and older is expected to triple during the same period, growing to 426 million. Therefore, the rising aging population is driving the growth of the columvi industry.

Key Players In The Global Columvi Market

Major companies operating in the columvi market are F. Hoffmann-La Roche Ltd.

Global Columvi Market Trends and Insights

The key trend in the columvi market is the development of innovative therapies, such as bispecific T-cell engagers (BiTEs), for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and large B-cell lymphoma (LBCL). BiTEs are engineered proteins designed to bind both T cells and cancer cells, effectively redirecting the immune system to target and destroy tumor cells. For instance, in June 2023, Roche, a Switzerland-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had granted accelerated approval for columvi (glofitamab-gxbm). This approval is for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) not otherwise specified or large B-cell lymphoma (LBCL) arising from follicular lymphoma, following two or more lines of systemic therapy. The approval was based on positive outcomes from the phase I/II NP30179 study, which evaluated Columvi as a fixed-duration therapy over 8.5 months in 132 patients. Among these, 30% had undergone prior CAR T-cell therapy, and 83% were refractory to their most recent treatment. The study reported durable remission, with an overall response rate (ORR) of 56% (74/132) and a complete response (CR) rate of 43% (57/132).

What Defines the Columvi Market?

The columvi market consists of sales of monoclonal antibodies, bispecific antibodies, small molecule drugs, and diagnostic products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Columvi Market Report 2026?

The columvi market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the columvi industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.